A Rapid Systematic Review of U.S. Food and Drug Administration–authorized COVID-19 Treatments

• by David J Sullivan, Massimo Franchini, Michael J Joyner, Arturo Casadevall, Daniele Focosi

• October 9, 2025

Permanent hypoparathyroidism following SARS-CoV-2 infection: a case report with two-year follow-up and literature review

• by Yizhi Zu, Hang Wang, Jinlin Wu, Cai Tang, Rui Han, Fang Fang

• May 25, 2026

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

• by Kathryn Wighton

• May 27, 2026

• 6 min

Characterization of post-COVID syndrome by self-perceived symptom severity stratified by infection wave: beyond COVID, a prospective, multicenter cohort study in Germany

• by Alexander Mertens, Judith Smith, Ingmar Bergs, Julia Fischer, Sarah Jansen, Sven Breitschwerdt, Elisabeth Pracht, Alexander Killer, Lukas Schipper, Nils Kuklik, Mirjam Frank, Julia Schwichtenberg, Siona Bührmann, Lina Zeissler, Michael Dreher, Jürgen Rockstroh, Hana Rohn, Clara Lehmann, Phil-Robin Tepasse, Börge Schmidt, Nico Dragano, Johannes Bode, Tom Luedde, Björn-Erik-Ole Jensen

• May 18, 2026